Atom | Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

Funder: National Institutes of Health (NIH)

Due Dates: August 9, 2023 (Application) | September 7, 2023 (AIDS Application)

Funding Amounts: Up to $500,000 total cost/year for Phase I (up to 2 years); up to $1,500,000 total cost/year for Phase II (up to 3 years). Budgets must reflect project needs; NIH pays contractors directly.

Summary: Supports U.S. small businesses in small molecule drug discovery and development for nervous system disorders, including clinical trial optional, with retention of intellectual property rights.

Key Information: Cooperative agreement with substantial NIH involvement; projects may enter at Discovery or Development stage; clinical trial optional; strong emphasis on milestones and go/no-go decisions; IP rights retained by awardees.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

Sign in to see full grant listing